iCo Therapeutics is a “Search and Development” company. By focusing efforts on development instead of research, iCo’s business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Subsequent development by iCo of these therapeutics may include drug delivery technologies—such as sustained release, biodegradable matrices, etc to extend patent coverage.
There is a significant decrease in development risk associated with targeting existing drugs, including:
* Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
* Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
* The target and mechanism of action has been identified.
iCo is actively looking to identify and acquire the rights to products that have a previous clinical history with potential for ophthalmic uses. iCo then employs various drug delivery technologies, re-doses or reformulates these existing products in order to enable ocular administration and gain additional intellectual property coverage for the product. This strategy enables partners to maximize the value of their existing assets with minimal risk of cross use / cross pricing issues.
| iCo Therapeutics Closes First Tranche of Non-Brokered $500,000 Private Placement | 01/30/2009 - 08:00 | $0Million |
| iCo Therapeutics Closes $1,140,450 Financing | 06/09/2008 - 07:00 | $1Million |
| iCo Therapeutics Announces $1,140,450 Financing | 06/08/2008 - 07:00 | $1Million |
| iCo Therapeutics, Beanstalk Capital Ltd deal, plan $1.8 million private placement | 10/17/2007 - 07:00 | $1Million |